RxSight, Inc. (NASDAQ:RXST) CEO Sells $2,406,000.00 in Stock

RxSight, Inc. (NASDAQ:RXST) CEO Ronald M. Md Kurtz sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $60.15, for a total transaction of $2,406,000.00. Following the completion of the sale, the chief executive officer now owns 764,610 shares in the company, valued at approximately $45,991,291.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

RxSight Stock Performance

NASDAQ:RXST opened at $62.19 on Wednesday. The stock has a 50-day simple moving average of $52.86 and a two-hundred day simple moving average of $43.32. The firm has a market capitalization of $2.30 billion, a PE ratio of -43.49 and a beta of 1.21. RxSight, Inc. has a 52-week low of $18.35 and a 52-week high of $66.54.

RxSight (NASDAQ:RXST) last announced its quarterly earnings data on Monday, May 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.08). RxSight had a negative net margin of 54.57% and a negative return on equity of 31.16%. The company had revenue of $29.51 million for the quarter, compared to the consensus estimate of $27.56 million. During the same quarter last year, the firm posted ($0.42) earnings per share. The company’s revenue was up 68.7% compared to the same quarter last year. Equities analysts forecast that RxSight, Inc. will post -0.94 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on RXST. Wells Fargo & Company increased their price target on RxSight from $61.00 to $68.00 and gave the company an “overweight” rating in a report on Tuesday. JPMorgan Chase & Co. increased their target price on RxSight from $40.00 to $62.00 and gave the company an “overweight” rating in a report on Thursday, February 29th. Needham & Company LLC raised their target price on RxSight from $64.00 to $75.00 and gave the stock a “buy” rating in a research report on Tuesday. Oppenheimer upped their price target on shares of RxSight from $61.00 to $72.00 and gave the company an “outperform” rating in a research report on Tuesday. Finally, Stifel Nicolaus increased their price objective on shares of RxSight from $64.00 to $68.00 and gave the stock a “buy” rating in a research note on Monday. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $60.63.

Institutional Trading of RxSight

Several institutional investors and hedge funds have recently modified their holdings of the company. Inspire Investing LLC bought a new position in RxSight in the 1st quarter worth $917,000. Swiss National Bank lifted its position in shares of RxSight by 16.2% in the first quarter. Swiss National Bank now owns 53,100 shares of the company’s stock valued at $2,739,000 after acquiring an additional 7,400 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of RxSight in the first quarter worth about $364,000. Quantbot Technologies LP grew its position in shares of RxSight by 8.4% during the first quarter. Quantbot Technologies LP now owns 53,686 shares of the company’s stock worth $2,769,000 after purchasing an additional 4,167 shares in the last quarter. Finally, Larson Financial Group LLC purchased a new stake in shares of RxSight during the first quarter worth about $51,000. 78.78% of the stock is currently owned by institutional investors.

RxSight Company Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.